Trial reportPloS one2018
ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Diagnostic accuracy and surgical outcomes of fluorescence-guided surgery in breast cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- Fluorescence imaging for real-time detection of breast cancer tumors using IV injection of indocyanine green with non-conventional imaging: a systematic review of preclinical and clinical studies of perioperative imaging technologies.Breast cancer research and treatment · 2024Pooled it
- Fluorescence guided surgery imaging systems for breast cancer identification: a systematic review.Journal of biomedical optics · 2024Pooled it
- Percutaneous Management of Breast Cancer: a Systematic Review.Current oncology reports · 2022Pooled it
- Pooled it
- Strong Dependence between Tryptophan-Related Fluorescence of Urine and Malignant Melanoma.International journal of molecular sciences · 2021Trial
- Intraoperative measurement of breast-conserving surgery margins: surgical application.Breast cancer research : BCR · 2026Review
- Fluorescence Discrimination of Cancer from Inflammation by Selective Targeting Folate Receptor α.Chemical & biomedical imaging · 2026Article
- Article
- Article
- Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy.Breast cancer research and treatment · 2025Article
- Tumor-selective dye-based histological electrophoresis enables intraoperative tumor diagnosis via tumor-specific enhancement.Theranostics · 2025Article
- Milk Exosome-Glow Nanosystem for Cancer Cellular and Tissue Bioimaging.Chemical & biomedical imaging · 2024Article
- Employing Raman Spectroscopy and Machine Learning for the Identification of Breast Cancer.Biological procedures online · 2024Article
- Optical Emission Spectroscopy for the Real-Time Identification of Malignant Breast Tissue.Diagnostics (Basel, Switzerland) · 2024Article
- Validation of a semi-quantitative scoring system and workflow for analysis of fluorescence quantification in companion animals.Frontiers in veterinary science · 2024Article
- Review
- Intraoperative Evaluation of Soft Tissue Sarcoma Surgical Margins with Indocyanine Green Fluorescence Imaging.Cancers · 2023Article
- ASO Author Reflections: Towards Fluorescence Guided Tumor Identification for Precision Breast Conserving Surgery.Annals of surgical oncology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResponse to neoadjuvant chemotherapy (NACT), particularly pathologic complete response (pCR), is an independent predictor of favorable clinical outcome in breast cancer (BC). The accuracy of residual disease measurement and reporting is of critical importance in treatment planning and prognosis for these patients. Currently, gross pathological evaluation of the residual tumor bed is the greatest determinant for accurate reporting of NACT response. Fluorescence imaging (FI) is a new technology that is being evaluated for use in the detection of tumors in different oncological conditions.
objectiveThe aim of this study was to evaluate whether indocyanine green fluorescence imaging (ICG-FI) is able to detect residual breast tumor tissue after NACT in breast surgical operative specimens.
methodsPatients who underwent NACT for BC and were admitted for breast surgery were selected for participation in this study. Free ICG (0.25 mg/kg) was injected intraoperatively. Tumor-to-background fluorescence ratio (TBFR) was calculated on ex vivo samples from the surgical specimen.
resultsOne hundred and seventy-two samples from nine breast surgical specimens were evaluated for their fluorescence intensity. Among them, 52 were malignant (30.2%) and 120 were benign (69.8%). The mean TBFR was 3.3 (SD 1.68) in malignant samples and 1.9 (SD 0.97) in benign samples (p = 0.0002). With a TBFR cut-off value of 1.3, the sensitivity, specificity, negative predictive value, false negative rate, and false positive rate of ICG-FI to predict residual tumoral disease in breast surgical samples post-NACT were 94.2%, 31.7%, 92.7%, 5.8%, and 68.3%, respectively. If we restricted our analysis to only patients who achieved pCR, the negative predictive value for ICG-FI was 100%.
conclusionsThese first observations indicate that ex vivo ICG-FI is sensitive but not sufficiently specific to discriminate between benign breast tissue and malignant residual tissue. Nevertheless, its negative predictive value seems sufficiently accurate to exclude the presence of residual breast tumor tissue on the operative specimen of patients treated by NACT, representing a potential tool to assist pathologists in the assessment of breast surgical specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.